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Summary Hormone concentrations in blood and total 12 h urine values were compared between 40 post-
menopausal women with breast cancer and 40 control women in a study which carefully controlled for the
possible confounding effects of age, weight and pregnancy history by individually matching cases and controls
on these factors. Breast cancer cases had received only surgical treatment for their localised disease, which was
diagnosed from 1 to 9 years before hormonal evaluation. Cases had 15% higher serum oestradiol levels
(P=0.02), 40% more urinary oestradiol (P=0.03) and 44% more urinary oestriol (P=0.04) than control
women. Cases also had higher levels of serum and urinary oestrone, but these differences were not statistically
significant. The percentages of serum oestradiol not bound to albumin or sex-hormone binding globulin did
not differ between cases and controls, nor were there statistically significant differences in the serum levels of
prolactin, sex-hormone binding globulin or dehydroepiandrosterone sulphate. These results provide further
support for the hypothesis that breast cancer risk is determined in part by post-menopausal serum oestrogen
concentration.
There is a substantial body of epidemiological, experimental
and clinical evidence for a role of oestrogens in the aetiology
of female breast cancer (Henderson et al., 1988). In
premenopausal women, the major source of endogenous oest-
rogens is the ovary. Menopause signals a marked decline in
the amount of circulating oestrogens and this decline is at
least part of the explanation for the decreased risk of breast
cancer associated with early menopause (Trichopoulos et al.,
1972). Although breast cancer incidence continues to rise
after menopause in US and European women, the rate of
increase in breast cancer incidence decreases substantially. In
post-menopausal women, the major source of oestrogen is
the peripheral conversion of androstenedione in fat tissue
(Grodin et al., 1973). This offers the most probable explana-
tion for the association of obesity with increased risk of
breast cancer in post-menopausal women (Lubin et al., 1985).
In women, 40-50% of plasma oestradiol (E2) is bound to
sex hormone-binding globulin (SHBG) and all but 2-4% of
the remainder is bound to albumin (Anderson, 1974). With
the development of relevant laboratory technology, attention
has focused on evaluating whether the free, non-protein
bound fraction of plasma E2 is higher in women with breast
cancer than in other women, as free E2 is considered to be
freely diffusible into cells and biologically available to recep-
tors in target tissues (Siiteri, 1980); this may also be true of
the non-SHGB bound E2 (Pardridge, 1986). This would fur-
ther explain the effect of body weight on breast cancer risk in
older women as increased weight is not only associated with
higher post-menopausal oestrogen levels but also with
reduced levels of SHBG and, therefore, with greater 'tissue
availability' of oestrogens (Siiteri et al., 1981).
A number of studies have compared endogenous oestrogen
and other hormone levels in post-menopausal breast cancer
cases and in control women by measuring these hormones in
blood or urine. Key and Pike (1988) have provided a comp-
rehensive summary of this literature. These studies generally
have shown that breast cancer cases have higher levels of
oestrogen, lower levels of SHBG, and a larger percentage of
non-protein bound E2 than controls. The outcome of statis-
tical tests in these studies has been mixed. This lack of
consistent statistical findings appears to be due, in part, to
certain aspects of the design of these studies as they have
varied in terms of sample size (many have been conducted on
small samples), matching criteria (few have matched on age
and many do not even report weight), the stage distribution
among the cases, the timing of the study in relationship to
treatment and the comparability of case and control source
populations. With special attention to each of the potential
problems of such studies, we have conducted a carefully
designed study of blood and urinary hormones in older




Breast cancer cases were identified from three health districts
in the southern section of Los Angeles County using inform-
ation collected by the Cancer Surveillance Program
(Hisserich et al., 1975), the population-based cancer registry
for Los Angeles County, and by the cancer registry of a
Southern California retirement community located in adja-
cent Orange County (Ross et al., 1980). A woman was
eligible for the study if her diagnosis of breast cancer had
been made at least 1 year after her last menstrual period, if
she had localised disease (versus regional disease or distant
metastases) that was treated only by surgery, if at least 6
months had passed since surgery for her breast cancer, if she
had had no recurrence of her breast cancer and if she had
intact ovaries. Case eligibility was further restricted to ex-
clude women with a history of thyroid disease and women
who had more than 1 year total lifetime use of exogenous
oestrogens or who had used exogenous oestrogens at all in
the past 12 months. Forty women with breast cancer were
recruited to participate in the study. All women were non-
Hispanic white women born in the USA.
Controls were selected from a cohort of women that we
are currently following at the retirement community. Restric-
ting selection to women in this community provided a com-
parable match to the social class of cases as both cases from
southern Los Angeles County and members of this adjacent
community tend to be of upper-middle socio-economic
status. One control was individually matched to each of the
40 cases in terms of age (within 5 years), weight (within 5 kg,
although in two cases it was necessary to expand this restric-
tion), and pregnancy history (never pregnant; at least one
pregnancy, but no full-term pregnancy; at least one full-term
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pregnancy). We also matched on height (within 2 cm).
Restrictions applied to the cases in terms of thyroid disease
and use of exogenous oestrogens were also applied to the
controls. As with cases, control women were US born non-
Hispanic whites.
Methods
Blood samples were collected from subjects in their homes
between 30 and 90min after the subject awakened in the
morning. Each blood drawing consisted of collecting four
5 ml samples which were drawn from an indwelling catheter
at 15 min intervals. Samples were collected into sterile tubes
without preservative. After centrifugation, the serum was
separated and stored in four 2 ml aliquots at - 20°C. Before
shipping, the samples were thawed and 1 ml from each of the
four samples was pooled. Serum samples were shipped on
dry ice to Endocrine Sciences Laboratory (Tarzana, CA,
USA) for prolactin (unpooled portions of sample 1 and
sample 4) and dehydroepiandrosterone sulphate (DHEA-S)
(unpooled portion of sample 2) assays and to the laboratory
of Howard L. Judd (University of California, Los Angeles,
USA) for measurement of oestrone (El), E2, percentage of
free E2 and SHBG using the pooled 4 ml sample. The iden-
tities of the specimens were not known to the laboratories;
the only identifier was a coded number unique for each
specimen; all assays were done at one time.
El and E2 were measured by the method of Devane et al.
(1975). Serum samples were extracted with diethyl ether,
chromatographed over microcelite columns and assayed
using antiserum developed against oestriol 3, 16, 17-trihemi-
succinate. The intra-assay coefficients of variation (CV) based
on control pools assayed concurrently were 11.2% for El and
17.5% for E2. The percentage of free E2 was determined by
the equilibrium dialysis method of Pardridge and Mietus
(1979); the intra-assay CV using concurrent control pools
was 12.9%. SHBG-binding capacity was measured by the
selective ammonium sulphate precipitation technique with the
use of a 3H-dihydrotestosterone reference (Rosner, 1972). For
SHBG-binding capacity, the intra-assay CV for concurrent
control pools was 9.5%. Prolactin concentrations were
measured by the method of Ehara et al. (1973) and DHEA-S
was measured directly on diluted serum samples after hyd-
rolysis with sulphatase and using a highly specific antiserum
made to DHEA-7-oxine conjugate. The intra-assay CVs were
10.2% for prolactin and 7.5% for DHEA-S.
Overnight urine specimens (12-h) were collected, with col-
lection beginning the evening before the morning that blood
was drawn. Urine collection was completed by 40 cases and
37 controls. The urine was treated with 15 ml of 20% acetic
acid, divided into 25 ml aliquots and stored at - 20°C. Ali-
quots of urine were coded and air freighted frozen on dry ice
to Melbourne, Australia (J.B.B.) where urinary levels of El,
E2 and oestriol (E3) were measured using a method involving
spectrophotofluorimetry and internal radioactive standards
(Brown, 1976). The intra-assay CVs were 10% for El, 15%
for E2 and 15% for E3. Urine hormone concentrations were
converted into absolute amounts by multiplying the concent-
ration by the total volume of urine collected.
The amount of free E2 was computed as the product of
total E2 and percentage of free E2. Hormone levels were
transformed to logarithmic (base 10) values to achieve app-
roximate normality of distributions for statitical analysis, and
geometric mean levels (and 95% confidence limits) are pre-
sented in the tables that follow. Quetelet's index was cal-
culated for each woman as the ratio of weight (kg) to the
square of height (m2). Paired t tests were used to test for
differences in geometric mean hormone values between breast
cancer cases and matched control women. The relationships
of the logarithm of hormone levels to age, age at menopause,
weight and time of day that the first blood sample was drawn
were assessed by graphical methods and by standard regres-
sion techniques and found not to differ significantly from
linear. Repeated measures (i.e. matched case-control)
analysis of covariance methods were used to test for
differences in geometric mean hormone levels adjusted for
these factors. The statistical analyses related to urinary hor-
mone levels were restricted to the 37 matched pairs for whom
we had adequate urine samples. All P values presented are
two-sided.
Results
Characteristics of breast cancer cases and individually
matched control women are presented in Table I. On
average, breast cancer cases were 1.5 years younger than
their respective controls (case age range 53-79; control age
range 56-81 years). In all other aspects, the two groups of
women were similar. Breast cancer cases had been diagnosed
from I to 9 years before hormonal evaluation and the mean
elapsed time since diagnosis was 4.1 years. Blood drawing
was begun between 07.30 and 08.50 for all subjects.
The differences in levels of serum E2 and amounts of
urinary E2 and E3 between breast cancer cases and matched
controls were statistically significant (Table II). Cases had
14.6% higher levels of serum E2 (P = 0.02), 40.0% more
urinary E2 (P = 0.03) and 43.5% more urinary E3(P = 0.04)
than did control women. Serum and urinary El
measurements were also greater in cases than controls
(10.6% and 23.1% respectively), but these differences were
not statistically significant. In terms of total urinary amounts
of the three oestrogens assayed, the levels of breast cancer
cases exceeded those of controls by 36.9% (P = 0.04). No
difference between cases and controls was observed in terms
of SHBG or in the percentage of serum E2 that was free (i.e.
not bound to protein), so that the observed difference in the
amount of free E2 (14.1% excess in cases) is solely a function
of higher total E2 levels in the cases.
The geometric mean prolactin levels of cases were 10.1%
lower than those of controls. This difference was reduced to
1.0% after adjustment was made for the time that blood
samples were drawn. Cases also had lower levels of DHEA-S
than did control women, but this difference was not statis-
tically significant.
Statistical adjustments for age, age at menopause and
weight in the analyses comparing oestrogen and SHBG levels
in cases and controls did not alter the results presented in
Table II. For urinary oestrogen levels, these adjustments
accentuated slightly the differences in means observed in the
univariate analyses.
Discussion
Previous studies have evaluated either urinary oestrogen ex-
cretion (Persson & Risholm, 1964; Marmorston et al., 1965;
Gronroos & Aho, 1968; Argeulles et al., 1973; Grattarola et
TableI Mean values(± standarddeviation)ofrelevantcharacteristics
of 40 post-menopausal women with breast cancer and individually




Age at sampling (years) 68.8 ± 7.6 70.3 ± 6.9
Age at last menstrual period (years) 49.8 ± 5.0 49.9 ± 3.8
Years since breast cancer diagnosis 4.1 ± 2.3
Weight (kg) 63.7 ± 12.0 63.2 ± 10.6
Height (m) 1.64 ± 0.07 1.64 ± 0.06
Quetelet's index (kgmr2) 23.7 + 3.6 23.5 ± 3.1
Time samples collected (hours past 8.3 + 0.3 8.2 ± 0.3
midnight)300 L. BERNSTEIN et al.
TableII Geometricmeanvalues(95% confidence limits)ofserumhormonesandurinary
estrogens of 40 post-menopausal women with breast cancer and individually matched
healthy population controls
Study group
Breast cancer Percentage Two-sided
Hormonefactora cases Controls difference' P value'
Serum
El (pmol dl-') 8.88 8.03 10.6 0.30
(7.77, 10.13) (6.18, 9.51)
E2 (pmol dl') 2.57 2.24 14.6 0.02
(2.32, 2.83) (2.03, 2.47)
Per cent freed 1.18 1.19 -0.8 0.77
(1.11, 1.24) (1.11, 1.27)
Amount free 2.97 2.61 14.1 0.08
(pmoll ') (2.61, 3.41) (2.31, 2.94)
SHBG (nmoll ') 42.5 40.3 5.5 0.60
(37.3, 48.5) (34.9, 46.5)
Prolactine (jugl -) 9.65 10.73 -10.1 0.43
(8.15, 11.44) (8.85, 13.00)
DHEA-S' (nmoldl-') 116.5 125.7 -7.4 0.65
(87.6, 154.6) (95.8, 165.4)
Urinef (nmol 12 h -'):
El 59.2 48.1 23.1 0.16
(51.4, 68.4) (37.0, 62.5)
E2 43.7 31.2 40.0 0.03
(37.4, 50.7) (24.6, 40.4)
E3 111.0 77.3 43.5 0.04
(92.6, 133.1) (58.9, 101.2)
E, + E2 + E3 218.6 159.7 36.9 0.04
(189.9, 252.0) (124.6, 204.8)
aE,,oestrone; E2,oestradiol; E3,oestriol; SHBG, sex-hormone binding globulin;
DHEA-S, dehydroepiandrosterone sulphate. bPercentage difference in geometric
means = (case-control)/control. CPaired t test. dArithmetic mean. 'Based on 34 matched
pairs. 'Based on 37 matched pairs.
al., 1974; Thijssen et al., 1975; Morreal et al., 1979) or
oestrogen concentrations in the blood (England et al., 1974;
McFadyen et al., 1976; Malarkey et al., 1977; Adami et al.,
1979; Drafta et al., 1980; Moore et al., 1982; Reed et al.,
1983, 1985; Secreto et al., 1983; Bruning et al., 1985; Siiteri et
al., 1986; Wysowski et al., 1987) of breast cancer cases and
controls. These studies have suggested that post-menopausal
breast cancer cases have higher endogenous oestrogen levels
than controls: five of the seven studies of urinary oestrogen
levels found evidence of greater oestrogen excretion in cases
(Persson & Risholm, 1964; Marmorston et al., 1965;
Arguelles et al., 1973; Grattarola et al., 1974; Morreal et
al.,1979); of the studies comparing blood levels of E, and E2
in cases and controls, three of five found higher E, (Adami et
al., 1979; Drafta et al., 1980; Reed et al., 1983) and eight of
11 found higher E2 levels in cases (England et al., 1974;
McFadyen et al., 1976; Malarkey et al., 1977; Drafta et al.,
1980; Moore et al., 1982; Reed et al., 1985; Bruning et al.,
1985; Siiteri et al., 1986). The results of the present study
provide evidence that the higher serum oestrogen concentra-
tions of breast cancer cases are mirrored in the urine by
higher urinary oestrogen excretion. Unlike most previous
studies, cases and controls were closely matched on weight in
our study, providing evidence that observed differences in
endogenous oestrogen production or metabolism between
women with breast cancer and control women is not due
entirely to differences in body weight.
Attention has focused recently on measuring the distribu-
tion of E2 binding to proteins in blood, following Siiteri's
suggestion that the risk of breast cancer may be increased
because of tissue exposure to higher levels of circulating,
biologically available E2 (Siiteri, 1980). Several recent studies
have found that breast cancer cases have higher percentages
of free E2 or greater amounts of free E2 than controls (Moore
et al., 1982, 1986; Reed et al., 1983, 1985; Bruning et al.,
1985; Langley et al., 1985; Ota et al., 1986; Siiteri et al., 1986;
Jones et al., 1987). Because higher weight is associated with
lower levels of SHBG and higher percentages of both free E2
and non-SHBG bound E2 (Siiteri et al., 1981), the reported
higher weight of cases in several of these studies can account,
at least in part, for the observed differences. In our study, in
which the cases and controls were matched on weight, the
average percentage of free E2 of cases and controls did not
differ. The fact that cases had about 14% more non-protein
bound E2 in their blood than controls simply reflects their
greater serum concentrations of E2-
Other hormones have been implicated in breast cancer
pathogenesis. In animal studies, prolactin can enhance
chemical transformation of breast epithelium and growth of
established or transplanted mammary tumours in rodents
(Welsch, 1981). After a completed pregnancy, prolactin levels
(Yu et al., 1981; Kwa et al., 1981; Musey et al., 1987) as well
as oestrogen levels (Bernstein et al., 1985, 1986) are reduced,
which may explain the protective effect of a full-term preg-
nancy on breast cancer risk. Nonetheless, in this study of
post-menopausal breast cancer patients, we find no
differences in the prolactin levels of cases and controls.
DHEA-S is regarded as an indicator of adrenal androgen
secretion (Lobo et al., 1981) and has been shown to be
significantly lower in Japanese women (at low risk of breast
cancer) than in British women (at high risk of breast cancer)
(Wang et al., 1976). It has been proposed that DHEA-S may
be involved in the development of breast cancer in older
women through the oestrogenic action of a metabolite, 5-
androstene-3p,17P-diol, on mammary tissue (Seymour-Munn
& Adams, 1983). We observed no significant differences in
DHEA-S among breast cancer cases and controls. Cases did,
in fact, have lower levels. We evaluated DHEA-S as aHORMONE LEVELS IN OLDER BREAST CANCER 301
measure of adrenal function as it is thought to represent
overall function; another measure of adrenal androgen secre-
tion which may provide an explanation for the striking
differences in oestrogen levels is androstenedione which is
converted to oestrone by muscle and adipose tissue (Tepper-
man, 1983). Unfortunately, we did not have adequate sera on
the majority of subjects to conduct this assay.
This work was supported by grants CA17054 and CA33512 from the
National Institutes of Health.
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